A preclinical trial using annatto tocotrienol in osteoporotic rats demonstrated that vitamin E tocotrienols are as effective as standard anti-osteoporosis therapy in men.
Able to completely prevent erosion of the bone surface and decreased bone formation associated with testosterone deficiency, annatto tocotrienol was as effective as testosterone enanthate, one of the standard therapies used to treat osteoporosis in men.
“This study serves as a basis for the application of annatto tocotrienol in hypogonadal men as an antiosteoporotic agent,” concluded the researchers, led by pharmacologist Ima-Nirwana Soelaiman of the Universiti Kebangsaan Malaysia.